Nothing Special   »   [go: up one dir, main page]

CR9716A - Bencimidazoles sustituidos como inhibidores de cinasa - Google Patents

Bencimidazoles sustituidos como inhibidores de cinasa

Info

Publication number
CR9716A
CR9716A CR9716A CR9716A CR9716A CR 9716 A CR9716 A CR 9716A CR 9716 A CR9716 A CR 9716A CR 9716 A CR9716 A CR 9716A CR 9716 A CR9716 A CR 9716A
Authority
CR
Costa Rica
Prior art keywords
bencimidazols
replaced
cinasa
inhibitors
compositions
Prior art date
Application number
CR9716A
Other languages
English (en)
Inventor
E Aikawa Mina
Amiri Payman
H Dove Jeffrey
Haskell Levine Barry
Mcbride Christopher
E Pick Teresa
J Poon Daniel
Ramurthy Savithri
A Renhowe Paul
Shafer Cynthia
Stuart Darrin
Subramanian Sharadha
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR9716A publication Critical patent/CR9716A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan nuevos compuestos de bencimidazol sustituidos de la Formula (I), composiciones, y metodos para la inhibicion de la actividad de cinasa asociada con tumorigenesis en un sujeto humano o animal. En ciertas modalidades, los compuestos y las composiciones son efectivos para inhibir la actividad de cuando menos una cinasa de serina/treonina o una cinasa de tirosina receptora.
CR9716A 2005-08-30 2008-02-07 Bencimidazoles sustituidos como inhibidores de cinasa CR9716A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71310805P 2005-08-30 2005-08-30
US71253905P 2005-08-30 2005-08-30
US73159105P 2005-10-27 2005-10-27
US77468406P 2006-02-17 2006-02-17

Publications (1)

Publication Number Publication Date
CR9716A true CR9716A (es) 2008-04-16

Family

ID=37434025

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9716A CR9716A (es) 2005-08-30 2008-02-07 Bencimidazoles sustituidos como inhibidores de cinasa

Country Status (37)

Country Link
US (6) US7482367B2 (es)
EP (2) EP1924577B1 (es)
JP (4) JP5210867B2 (es)
KR (2) KR20080039965A (es)
AR (2) AR055622A1 (es)
AT (2) ATE503751T1 (es)
AU (2) AU2006284666B2 (es)
BR (2) BRPI0615314A2 (es)
CA (2) CA2620472C (es)
CR (1) CR9716A (es)
CU (1) CU23784B7 (es)
CY (2) CY1111871T1 (es)
DE (1) DE602006021036D1 (es)
DK (2) DK1924577T3 (es)
EA (1) EA014230B1 (es)
EC (2) ECSP088210A (es)
ES (1) ES2374451T3 (es)
GE (1) GEP20105004B (es)
GT (1) GT200600394A (es)
HK (2) HK1117519A1 (es)
HN (1) HN2008000317A (es)
HR (2) HRP20110312T1 (es)
IL (2) IL189080A (es)
MA (2) MA29915B1 (es)
MY (2) MY163886A (es)
NI (1) NI200800060A (es)
NO (1) NO20081476L (es)
NZ (2) NZ565450A (es)
PE (2) PE20070335A1 (es)
PL (2) PL1926722T3 (es)
PT (2) PT1924577E (es)
RS (1) RS52099B (es)
SI (2) SI1924577T1 (es)
SM (1) SMAP200800022A (es)
TN (2) TNSN08089A1 (es)
TW (2) TW200804345A (es)
WO (2) WO2007030377A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
GB0609378D0 (en) * 2006-05-11 2006-06-21 Novartis Ag Organic compounds
SI2046292T1 (sl) * 2006-07-21 2010-06-30 Novartis Ag Formulacije za benzimidazolil piridil etre
PE20080766A1 (es) * 2006-08-30 2008-06-15 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen
RU2009114745A (ru) * 2006-09-19 2010-10-27 Новартис АГ (CH) Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования
RU2483064C2 (ru) * 2007-03-02 2013-05-27 Новартис Аг Твердые формы ингибитора raf-киназы
JP2010528032A (ja) * 2007-05-23 2010-08-19 ノバルティス アーゲー 甲状腺癌の処置のためのｒａｆ阻害剤
AR066845A1 (es) 2007-06-05 2009-09-16 Takeda Pharmaceutical Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
JP5350247B2 (ja) * 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
CN102065859B (zh) * 2008-06-13 2012-10-03 诺瓦提斯公司 用于神经纤维瘤病的取代的苯并咪唑类
JP2011527703A (ja) * 2008-07-11 2011-11-04 ノバルティス アーゲー （ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物
WO2010051176A1 (en) * 2008-10-29 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2399921B1 (en) 2008-12-01 2015-08-12 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
JP2011020936A (ja) * 2009-07-14 2011-02-03 Lotte Co Ltd 口臭除去剤
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
WO2011044072A1 (en) 2009-10-05 2011-04-14 Novartis Ag Combination of raf-265 and an activator of ampk for use in the treatment of a proliferative disease
EP2640387A4 (en) * 2010-11-19 2014-08-20 Glaxosmithkline Ip No 2 Ltd METHOD OF TREATMENT USING BRAF INHIBITOR
JP6021805B2 (ja) 2011-04-18 2016-11-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
CA2846454A1 (en) 2011-08-31 2013-05-10 Novartis Ag Synergistic combinations of pi3k- and mek-inhibitors
EP2776417B1 (en) * 2011-11-09 2018-10-31 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
MX354725B (es) 2011-11-11 2018-03-16 Novartis Ag Metodo de tratamiento de una enfermedad proliferativa.
WO2013078264A1 (en) 2011-11-23 2013-05-30 Novartis Ag Pharmaceutical formulations
SG11201407238VA (en) 2012-05-15 2014-12-30 Cancer Rec Tech Ltd 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
EP2916834A1 (en) 2012-11-08 2015-09-16 Novartis AG Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
SG11201507730UA (en) 2013-03-21 2015-10-29 Novartis Ag Combination therapy comprising a b-raf inhibitor and a second inhibitor
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3660050A1 (en) 2014-03-14 2020-06-03 Novartis AG Antibody molecules to lag-3 and uses thereof
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
SG11201706756VA (en) 2015-03-10 2017-09-28 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
US9890187B2 (en) 2015-06-26 2018-02-13 Epos-Iasis Research And Development, Ltd. Prototype systems of theranostic biomarkers for in vivo molecular management of cancer
DK3316857T3 (da) 2015-06-30 2021-10-18 Sequessome Tech Holdings Limited Multifasiske sammensætninger
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
AU2016348388B2 (en) 2015-11-03 2023-11-30 Janssen Biotech, Inc. Antibodies specifically binding PD-1 and their uses
CN105481944B (zh) * 2015-12-10 2019-01-08 华南农业大学 一种苯并咪唑衍生物二肽铜配合物及其制备方法和应用
US20180371093A1 (en) 2015-12-17 2018-12-27 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
US11242332B2 (en) 2017-03-15 2022-02-08 Sumitomo Dainippon Pharma Co., Ltd. Method for producing benzimidazole derivative
LT3612519T (lt) * 2017-04-18 2022-03-25 Eli Lilly And Company Fenil-2-hidroksi-acetilamino-2-metil-fenilo junginiai
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
MX2019015885A (es) 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
JP7416716B2 (ja) 2017-12-28 2024-01-17 トラクト ファーマシューティカルズ インコーポレイテッド 円柱上皮幹細胞のための幹細胞培養系およびそれに関連した使用法
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
US20230183204A9 (en) * 2018-11-07 2023-06-15 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
JP2022517316A (ja) 2019-01-11 2022-03-08 ネイジス ファーマシューティカルズ インコーポレイテッド ロイコトリエン合成阻害剤
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894037A (en) * 1971-05-24 1975-07-08 Ciba Geigy Corp Certain isothiocyanobenzimidazoles
CH634306A5 (de) * 1977-04-12 1983-01-31 Ciba Geigy Ag Benzimidazolderivate, verfahren zu ihrer herstellung und anthelmintische mittel enthaltend diese verbindungen als wirkstoffe.
US4294926A (en) * 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4319039A (en) * 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
JPS5889191A (ja) 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
US4430502A (en) * 1982-08-13 1984-02-07 The Upjohn Company Pyridinyl substituted benzimidazoles and quinoxalines
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4911165A (en) * 1983-01-12 1990-03-27 Ethicon, Inc. Pliabilized polypropylene surgical filaments
GB8307865D0 (en) * 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4782084A (en) * 1987-06-29 1988-11-01 Merck & Co., Inc. HMG-COA reductase inhibitors
US4885314A (en) 1987-06-29 1989-12-05 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4820850A (en) * 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5290946A (en) * 1988-10-13 1994-03-01 Sandoz Ltd. Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes
US5118853A (en) * 1988-10-13 1992-06-02 Sandoz Ltd. Processes for the synthesis of 3-disubstituted aminoacroleins
US4929437A (en) * 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5189164A (en) * 1989-05-22 1993-02-23 Sandoz Ltd. Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
JPH06759B2 (ja) * 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
US5420245A (en) * 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
US5041453A (en) * 1990-05-30 1991-08-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4
FR2677020B1 (fr) * 1991-05-31 1993-08-27 Cird Galderma Composes derives de benzimidazole, leur procede de preparation et leur utilisation dans les domaines therapeutique et cosmetique.
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
EP0604181A1 (en) 1992-12-21 1994-06-29 Eli Lilly And Company Antitumor compositions and method of treatment
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2118985A1 (en) 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
US5843941A (en) * 1993-05-14 1998-12-01 Genentech, Inc. Ras farnesyl transferase inhibitors
US5602098A (en) * 1993-05-18 1997-02-11 University Of Pittsburgh Inhibition of farnesyltransferase
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5852046A (en) 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
US5661152A (en) * 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5484799A (en) 1993-12-09 1996-01-16 Abbott Laboratories Antifungal dorrigocin derivatives
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
HUT72440A (en) 1994-03-31 1996-04-29 Bristol Myers Squibb Co Imidazole-containing inhibitors of farnesyl protein transferase and pharmaceutical compositions containing them
US5523430A (en) * 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US5510510A (en) * 1994-05-10 1996-04-23 Bristol-Meyers Squibb Company Inhibitors of farnesyl protein transferase
US6358932B1 (en) * 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) * 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5571792A (en) * 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
CA2155448A1 (en) 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
EP0701907A1 (en) 1994-09-13 1996-03-20 Agfa-Gevaert N.V. A dye donor element for use in a thermal dye transfer process
US6037136A (en) * 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5741789A (en) * 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US6020343A (en) * 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
ATE218556T1 (de) * 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
JP3063162B2 (ja) * 1995-12-28 2000-07-12 藤沢薬品工業株式会社 ベンズイミダゾール誘導体
GB9602029D0 (en) * 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
EA003319B1 (ru) * 1996-04-12 2003-04-24 Джи. Ди. Сирл Энд Ко. Производные замещенного бензолсульфонамида - пролекарства ингибиторов cox-2
US6281193B1 (en) * 1996-05-23 2001-08-28 Applied Research Systems Ars Holding N.V. Compounds that inhibit the binding of RAF-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
FR2751649B1 (fr) * 1996-07-26 1998-08-28 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2273083C (en) * 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6127380A (en) * 1997-02-18 2000-10-03 American Home Products Corporation 4-aminoalkoxy-1H-benzoimidazoles
US5932600A (en) * 1997-03-14 1999-08-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
EP0966465B1 (en) * 1997-03-14 2003-07-09 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
BR9810651A (pt) * 1997-07-03 2000-10-03 Neurogen Corp Certos derivados de diarilimidazol; uma nova classe de ligantes npy especìficos
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
FR2766822B1 (fr) * 1997-07-30 2001-02-23 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) * 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
JP2002516322A (ja) * 1998-05-22 2002-06-04 スミスクライン・ビーチャム・コーポレイション 新規２−アルキル置換イミダゾール化合物
US6420555B1 (en) * 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
FR2780973B1 (fr) * 1998-07-09 2001-10-05 Hoechst Marion Roussel Inc Procede de preparation du 4-(3-pyridinyl)-1h-imidazole, et les intermediaires mis en oeuvre
DE19834751A1 (de) * 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
US6211177B1 (en) * 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
US7351834B1 (en) * 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE286896T1 (de) * 1999-04-12 2005-01-15 Aventis Pharma Ltd Substituierte bicyclische heteroaryl-verbindungen als integrin antagonisten
CA2373883A1 (en) 1999-07-02 2001-01-11 Stuart A. Lipton Method of reducing neuronal injury or apoptosis
EP1263753B1 (en) 2000-03-06 2004-05-06 SmithKline Beecham plc Imidazol derivatives as raf kinase inhibitors
AU2001249397A1 (en) 2000-03-24 2001-10-08 Cor Therapeutics, Inc. Oxindole inhibitors of factor xa
AU2001249399A1 (en) 2000-03-24 2001-10-08 Cor Therapeutics, Inc. Isoquinolone inhibitors of factor xa
US20020042405A1 (en) * 2000-07-27 2002-04-11 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
JP2001322903A (ja) 2000-05-15 2001-11-20 Kumiai Chem Ind Co Ltd 農園芸用殺菌剤組成物
WO2002018654A1 (en) * 2000-08-30 2002-03-07 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
JP4734705B2 (ja) 2000-10-31 2011-07-27 三菱化学株式会社 リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
DE10060292A1 (de) * 2000-12-05 2002-06-20 Aventis Pharma Gmbh Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament
WO2002060879A2 (en) * 2000-12-15 2002-08-08 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
CA2435820A1 (en) * 2001-02-08 2002-08-15 Karo Bio Ab Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
US20050038022A1 (en) * 2001-03-26 2005-02-17 Unisearch Limited Method for treatment of cancer and compositions for use therein
HUP0303829A3 (en) 2001-04-16 2006-02-28 Tanabe Seiyaku Co Large conductance calcium-acitvated k channel opener compounds, use thereof and pharmaceutical compositions containing them
US6855714B2 (en) * 2001-07-06 2005-02-15 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
EP1427408A4 (en) 2001-09-17 2005-10-26 Bristol Myers Squibb Co CYCLIC HYDROXAMINE ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-a-CONVERTASE (TACE TNF-a-CONVERTING ENZYM)
WO2003030902A1 (en) * 2001-10-09 2003-04-17 Tularik Inc. Imidazole derivates as anti-inflammatory agents
US7039413B2 (en) * 2001-10-24 2006-05-02 Ntt Docomo, Inc. Mobile station transfer control system, cell transfer control method, mobile station, cell transfer control method at mobile station, cell transfer control program, control apparatus, and allocating method of communication resources
TW200300140A (en) 2001-11-14 2003-05-16 Novartis Ag Organic compounds
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
JP4136395B2 (ja) 2002-02-22 2008-08-20 クミアイ化学工業株式会社 農園芸用殺菌剤組成物
KR20110015702A (ko) * 2002-03-29 2011-02-16 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치환된 벤자졸 및 ｒａｆ 키나아제 저해제로서의 그들의 이용
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
CA2483504A1 (en) 2002-04-25 2003-11-06 Teijin Limited 4,4-(disubstituted)piperidine derivatives with ccr3 antagonism
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
PL375256A1 (en) 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-oxadiazoles as modulators of metabotropic glutamate receptor-5
WO2004026859A1 (en) * 2002-09-18 2004-04-01 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tgf) inhibitors
WO2004035056A1 (en) 2002-10-13 2004-04-29 Neurosearch A/S Use of skca channel blocking drugs for combating parkinson's disease
EP1556140A4 (en) 2002-10-15 2006-04-19 Synta Pharmaceuticals Corp NEW COMPOUNDS
US20050054705A1 (en) * 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
CA2520124A1 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of benzazole compounds for immunopotentiation
RU2374241C2 (ru) 2003-05-20 2009-11-27 Новартис Аг N-ацилированные азотсодержащие гетероциклические соединения в качестве лигандов ppar-рецепторов, активируемых пролифератором пероксисомы
JP2007500241A (ja) 2003-05-29 2007-01-11 シンタ ファーマシューティカルズ コーポレーション 過度の骨量減少に関連する疾患の予防及び治療用の複素環化合物
EP1646628A1 (en) 2003-07-08 2006-04-19 Novartis AG Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
EP1654251A4 (en) 2003-08-14 2009-03-11 Smithkline Beecham Corp CHEMICAL COMPOUNDS
EP2409704B1 (en) 2003-09-26 2017-09-20 Exelixis, Inc. c-Met modulators and methods of use
ES2327418T3 (es) * 2003-10-16 2009-10-29 Novartis Vaccines And Diagnostics, Inc. Benzazoles sustituidos y uso de los mismos como inhibidores de la quinasa raf.
US7626030B2 (en) 2004-01-23 2009-12-01 Amgen Inc. Compounds and methods of use
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
SI2046292T1 (sl) * 2006-07-21 2010-06-30 Novartis Ag Formulacije za benzimidazolil piridil etre

Also Published As

Publication number Publication date
BRPI0615314A2 (pt) 2011-05-17
DK1924577T3 (da) 2011-05-16
AU2006284666A1 (en) 2007-03-08
NZ565450A (en) 2011-04-29
SI1926722T1 (sl) 2012-01-31
JP2009507026A (ja) 2009-02-19
US20100256375A1 (en) 2010-10-07
MA29915B1 (fr) 2008-11-03
IL189194A (en) 2013-09-30
JP2009507794A (ja) 2009-02-26
EA200800441A1 (ru) 2008-08-29
HN2008000317A (es) 2011-02-16
TW200804346A (en) 2008-01-16
NZ565451A (en) 2011-05-27
KR20080039964A (ko) 2008-05-07
IL189080A0 (en) 2008-08-07
TWI387592B (zh) 2013-03-01
PT1924577E (pt) 2011-07-04
SI1924577T1 (sl) 2011-07-29
US7767820B2 (en) 2010-08-03
JP5210866B2 (ja) 2013-06-12
ATE526325T1 (de) 2011-10-15
PL1924577T3 (pl) 2011-09-30
US20090170904A1 (en) 2009-07-02
HK1117523A1 (en) 2009-01-16
HRP20110312T1 (hr) 2011-08-31
JP2013060457A (ja) 2013-04-04
TNSN08089A1 (en) 2009-07-14
AU2006287688A1 (en) 2007-03-15
CY1111871T1 (el) 2015-11-04
HK1117519A1 (en) 2009-01-16
US8592459B2 (en) 2013-11-26
US7732465B2 (en) 2010-06-08
PE20070335A1 (es) 2007-04-21
BRPI0615309A2 (pt) 2011-05-17
SMP200800022B (it) 2008-04-02
MY163886A (en) 2017-11-15
CA2619966A1 (en) 2007-03-08
EP1926722A1 (en) 2008-06-04
TW200804345A (en) 2008-01-16
EP1924577A1 (en) 2008-05-28
GEP20105004B (en) 2010-06-10
BRPI0615309B1 (pt) 2021-07-27
AU2006287688B2 (en) 2010-08-19
CA2620472A1 (en) 2007-03-15
US20070049622A1 (en) 2007-03-01
RS52099B (en) 2012-06-30
MY148694A (en) 2013-05-31
CU23784B7 (es) 2012-02-15
CU20080027A7 (es) 2010-12-08
EA014230B1 (ru) 2010-10-29
ATE503751T1 (de) 2011-04-15
ECSP088210A (es) 2008-03-26
AR055622A1 (es) 2007-08-29
US20080287682A1 (en) 2008-11-20
JP5210867B2 (ja) 2013-06-12
ES2374451T3 (es) 2012-02-16
US20100234394A1 (en) 2010-09-16
WO2007027950A1 (en) 2007-03-08
ECSP088218A (es) 2008-03-26
NI200800060A (es) 2009-03-03
IL189194A0 (en) 2008-06-05
PT1926722E (pt) 2012-01-11
DK1926722T3 (da) 2011-12-19
EP1926722B1 (en) 2011-09-28
IL189080A (en) 2013-05-30
DE602006021036D1 (de) 2011-05-12
US20070161680A1 (en) 2007-07-12
NO20081476L (no) 2008-03-26
EP1924577B1 (en) 2011-03-30
US7482367B2 (en) 2009-01-27
SMAP200800022A (it) 2008-04-02
AU2006284666B2 (en) 2011-04-28
JP2013060458A (ja) 2013-04-04
KR20080039965A (ko) 2008-05-07
WO2007030377A1 (en) 2007-03-15
TNSN08088A1 (en) 2009-07-14
AR057109A1 (es) 2007-11-14
HRP20110939T1 (hr) 2012-01-31
CY1112157T1 (el) 2015-12-09
PE20070427A1 (es) 2007-04-21
PL1926722T3 (pl) 2012-02-29
MA29772B1 (fr) 2008-09-01
CA2620472C (en) 2013-12-24
GT200600394A (es) 2008-03-17

Similar Documents

Publication Publication Date Title
CR9716A (es) Bencimidazoles sustituidos como inhibidores de cinasa
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
NI201100052A (es) Derivados de picolinamida como inhibidores de cinasa.
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
ECSP11011098A (es) Nuevas pirazol-4-n-alcoxicarboxamidas cómo microbicidas.
CU23778B7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
CR9677A (es) Derivados de pirrolo(2,3-b) piridina como inhibidores de proteina cinasa
UY30600A1 (es) Compuestos novedosos
CR11264A (es) Compuestos de 5-(4-halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
ECSP088782A (es) Compuestos nuevos
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
EA201100426A1 (ru) Бициклические ингибиторы киназы
UY30297A1 (es) Inhibidores de la quinasa c-fms-i
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
EA201000428A1 (ru) Оксадиазол- и оксазолзамещенные производные бензимидазола и индола как ингибиторы dgat1
EA201070169A1 (ru) 2,3-дигидробензо[1,4]диоксин-2-илметиловые производные в качестве альфа2с антагонистов для применения в лечении заболеваний перифирической центральной нервной системы
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
ECSP099675A (es) Compuestos heterocíclicos, composición y métodos de uso
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
UA94055C2 (en) Substituted benzimidazoles and methods of preparation
GT200500219A (es) 4-(2,4-dicloro-5-metoxifenil)amino-6-metoxi-7([5-amino-sustituido)metil]-3-furil)-3-quinolincarbonitrilos comoinhibidores de quinasa.
SV2008002831A (es) Bencimidazoles sustituidos como inhibidores de cinasa

Legal Events

Date Code Title Description
FC Refusal